The Depo-Provera docket in MDL 3140 (N.D. Fla., Judge M. Casey Rodgers) surged by 204 cases in the past week alone, with OnderLaw LLC filing 56 complaints and Seeger Weiss adding 17, as firms race to build inventories ahead of Pfizer's pending preemption ruling. The FDA's December 2025 meningioma warning label update has significantly weakened Pfizer's federal preemption defense, and supplemental briefing ordered by Judge Rodgers following oral argument last September remains under advisement. The rapid multi-firm accumulation—also including Gori Law Firm PC (16), Weitz & Luxenberg PC (13), and Simmons Hanly Conroy LLP (11)—signals that plaintiff steering committees view the 3,099-case MDL as a priority growth area as the preemption motion nears resolution.
The Environmental Protection Agency moved March 13 to weaken limits on ethylene oxide emissions, a regulatory rollback that directly undermines defense arguments in the EtO sterilization litigation that plaintiffs' alleged exposures fall below actionable thresholds. The proposed rule change comes as ethylene oxide plaintiffs pursue claims against sterilization facilities and medical device manufacturers for cancers including lymphoma and leukemia, with the new EPA position likely to complicate defendants' efforts to dispute causation at upcoming Daubert hearings. Plaintiff attorneys are expected to seize on the regulatory retreat as evidence that industry pressure, not science, is driving exposure standards.
Novo Nordisk and Eli Lilly face accelerating bifurcated liability across two parallel GLP-1 MDLs before Judge Karen Marston in the Eastern District of Pennsylvania. MDL 3094 (gastroparesis) added 23 new filings last week led by Morgan & Morgan PA's 15 complaints, while MDL 3163 (NAION vision loss) grew by six cases including three from Parker Waichman LLP, even as the latter docket's leadership team was only appointed March 3, 2026. The distinct injury tracks—now totaling 3,363+ gastroparesis cases versus 54 NAION cases—reflect plaintiffs' strategy of segmenting by FDA-recognized adverse event profile, with discovery into Novo Nordisk's clinical trial data ongoing in the larger gastroparesis proceeding.
Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
